deltatrials
Terminated PHASE2 NCT00927953

Treatment of West Nile Virus With MGAWN1

Phase 2, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MGAWN1 in Subjects With Laboratory-documented West Nile Fever or Suspected Central Nervous System Infection Due to West Nile Virus

Sponsor: MacroGenics

Conditions Acute Flaccid Paralysis Encephalitis Meningitis West Nile Fever West Nile Neuroinvasive Disease West Nile Virus Infection
Interventions MGAWN1 Placebo - normal saline
Updated 8 times since 2017 Last updated: Feb 4, 2022 Started: May 31, 2009 Primary completion: Feb 28, 2011 Completion: May 31, 2011

Listed as NCT00927953, this PHASE2 trial focuses on Acute Flaccid Paralysis and Encephalitis and remains terminated or withdrawn. Sponsored by MacroGenics, it has been updated 8 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Mar 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Mar 2022 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MacroGenics
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: MacroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.